Cover Page
Cover Page - shares | 6 Months Ended | |
Jun. 27, 2021 | Jul. 27, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 27, 2021 | |
Document Transition Report | false | |
Entity File Number | 1-5353 | |
Entity Registrant Name | TELEFLEX INCORPORATED | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 23-1147939 | |
Entity Address, Address Line One | 550 E. Swedesford Rd., Suite 400 | |
Entity Address, City or Town | Wayne | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 19087 | |
City Area Code | 610 | |
Local Phone Number | 225-6800 | |
Title of 12(b) Security | Common Stock, par value $1.00 per share | |
Trading Symbol | TFX | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Smaller Reporting Company | false | |
Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 46,801,138 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0000096943 | |
Current Fiscal Year End Date | --12-31 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Income Statement [Abstract] | ||||
Net revenues | $ 713,473 | $ 567,034 | $ 1,347,398 | $ 1,197,676 |
Cost of goods sold | 315,917 | 288,662 | 605,315 | 585,680 |
Gross profit | 397,556 | 278,372 | 742,083 | 611,996 |
Selling, general and administrative expenses | 224,159 | 191,193 | 427,307 | 338,989 |
Research and development expenses | 33,283 | 29,364 | 63,230 | 56,760 |
Restructuring and impairment charges | 11,494 | 19,005 | 19,492 | 20,351 |
Income from continuing operations before interest and taxes | 128,620 | 38,810 | 232,054 | 195,896 |
Interest expense | 16,171 | 15,682 | 32,969 | 31,121 |
Interest income | (232) | (163) | (891) | (742) |
Loss on extinguishment of debt | 12,986 | 0 | 12,986 | 0 |
Income from continuing operations before taxes | 99,695 | 23,291 | 186,990 | 165,517 |
Taxes on income from continuing operations | 16,412 | 11,848 | 28,840 | 22,922 |
Income from continuing operations | 83,283 | 11,443 | 158,150 | 142,595 |
Operating (loss) income from discontinued operations | (46) | 22 | (47) | 18 |
Tax (expense) benefit on operating loss from discontinued operations | (11) | 9 | (11) | 7 |
(Loss) income from discontinued operations | (35) | 13 | (36) | 11 |
Net income | $ 83,248 | $ 11,456 | $ 158,114 | $ 142,606 |
Basic: | ||||
Income from continuing operations (in dollars per share) | $ 1.78 | $ 0.25 | $ 3.39 | $ 3.07 |
Loss from discontinued operations (in dollars per share) | 0 | 0 | (0.01) | 0 |
Net income (in dollars per share) | 1.78 | 0.25 | 3.38 | 3.07 |
Diluted: | ||||
Income from continuing operations (in dollars per share) | 1.76 | 0.24 | 3.34 | 3.02 |
Loss from discontinued operations (in dollars per share) | 0 | 0 | (0.01) | 0 |
Net income (in dollars per share) | $ 1.76 | $ 0.24 | $ 3.33 | $ 3.02 |
Weighted average common shares outstanding | ||||
Basic (in shares) | 46,741 | 46,442 | 46,719 | 46,412 |
Diluted (in shares) | 47,433 | 47,242 | 47,420 | 47,237 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 83,248 | $ 11,456 | $ 158,114 | $ 142,606 |
Other comprehensive income (loss), net of tax: | ||||
Foreign currency translation, net of tax of $1,002, $2,295, $404, and $(5,286) for the three and six months periods, respectively | 6,080 | 17,654 | (17,995) | (545) |
Pension and other postretirement benefit plans adjustment, net of tax of $(390), $(404), $(903), and $(926) for the three and six months periods, respectively | 1,298 | 1,345 | 2,909 | 3,034 |
Derivatives qualifying as hedges, net of tax of $39, $64, $72, and $436 for the three and six months periods, respectively | 397 | (1,095) | 424 | (4,912) |
Other comprehensive income (loss), net of tax: | 7,775 | 17,904 | (14,662) | (2,423) |
Comprehensive income | $ 91,023 | $ 29,360 | $ 143,452 | $ 140,183 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Foreign currency translation, tax | $ 1,002 | $ 2,295 | $ 404 | $ (5,286) |
Pension and other postretirement benefits plans adjustment, tax | (390) | (404) | (903) | (926) |
Derivatives qualifying as hedges, tax | $ 39 | $ 64 | $ 72 | $ 436 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 27, 2021 | Dec. 31, 2020 |
Current assets | ||
Cash and cash equivalents | $ 361,781 | $ 375,880 |
Accounts receivable, net | 414,195 | 395,071 |
Inventories | 490,318 | 513,196 |
Prepaid expenses and other current assets | 116,818 | 115,436 |
Prepaid taxes | 27,180 | 22,842 |
Current assets held-for-sale | 26,936 | 0 |
Total current assets | 1,437,228 | 1,422,425 |
Property, plant and equipment, net | 449,754 | 473,912 |
Operating lease assets | 115,110 | 100,635 |
Goodwill | 2,537,432 | 2,585,966 |
Intangible assets, net | 2,381,329 | 2,519,746 |
Deferred tax assets | 8,442 | 8,073 |
Other assets | 41,666 | 41,802 |
Noncurrent assets held-for-sale | 95,426 | 0 |
Total assets | 7,066,387 | 7,152,559 |
Current liabilities | ||
Current borrowings | 92,500 | 100,500 |
Accounts payable | 106,567 | 102,520 |
Accrued expenses | 138,280 | 136,276 |
Payroll and benefit-related liabilities | 121,822 | 122,366 |
Accrued interest | 5,522 | 7,135 |
Income taxes payable | 14,836 | 17,361 |
Other current liabilities | 46,265 | 53,869 |
Liabilities held-for-sale | 1,056 | 0 |
Total current liabilities | 526,848 | 540,027 |
Long-term borrowings | 2,215,666 | 2,377,888 |
Deferred tax liabilities | 483,269 | 484,678 |
Pension and postretirement benefit liabilities | 51,179 | 74,499 |
Noncurrent liability for uncertain tax positions | 10,078 | 10,127 |
Noncurrent operating lease liabilities | 101,302 | 86,097 |
Other liabilities | 211,943 | 242,786 |
Total liabilities | 3,600,285 | 3,816,102 |
Commitments and contingencies | ||
Total shareholders' equity | 3,466,102 | 3,336,457 |
Total liabilities and shareholders' equity | $ 7,066,387 | $ 7,152,559 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 27, 2021 | Jun. 28, 2020 | |
Cash flows from operating activities of continuing operations: | ||
Net income | $ 158,114 | $ 142,606 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Income (loss) from discontinued operations | 36 | (11) |
Depreciation expense | 35,982 | 34,461 |
Intangible asset amortization expense | 83,867 | 78,638 |
Deferred financing costs and debt discount amortization expense | 2,388 | 1,984 |
Loss on extinguishment of debt | 12,986 | 0 |
Fair value step up of acquired inventory sold | 3,993 | 1,707 |
Changes in contingent consideration | 11,428 | (29,951) |
Impairment of long-lived assets | 6,739 | 0 |
Stock-based compensation | 11,693 | 8,482 |
Deferred income taxes, net | 1,050 | 1,055 |
Payments for contingent consideration | 0 | (79,771) |
Interest benefit on swaps designated as net investment hedges | (9,126) | (9,805) |
Other | (16,679) | (18,981) |
Changes in assets and liabilities, net of effects of acquisitions and disposals: | ||
Accounts receivable | (23,159) | 45,843 |
Inventories | (13,648) | (34,875) |
Prepaid expenses and other assets | (16,551) | 11,819 |
Accounts payable, accrued expenses and other liabilities | 32,625 | (26,449) |
Income taxes receivable and payable, net | (16,663) | 7,257 |
Net cash provided by operating activities from continuing operations | 265,075 | 134,009 |
Cash flows from investing activities of continuing operations: | ||
Expenditures for property, plant and equipment | (36,659) | (39,052) |
Proceeds from sale of assets | 404 | 400 |
Payments for businesses and intangibles acquired, net of cash acquired | (3,539) | (265,895) |
Deposits | (1,250) | 0 |
Net interest proceeds on swaps designated as net investment hedges | 9,288 | 9,986 |
Net cash used in investing activities from continuing operations | (31,756) | (294,561) |
Cash flows from financing activities of continuing operations: | ||
Proceeds from new borrowings | 400,000 | 1,010,000 |
Reduction in borrowings | (575,000) | (500,000) |
Debt extinguishment, issuance and amendment fees | (9,774) | (7,727) |
Net proceeds from share based compensation plans and the related tax impacts | 6,339 | 2,668 |
Payments for contingent consideration | (30,489) | (60,947) |
Dividends paid | (31,793) | (31,558) |
Net cash (used in) provided by financing activities from continuing operations | (240,717) | 412,436 |
Cash flows from discontinued operations: | ||
Net cash used in operating activities | (371) | (317) |
Net cash used in discontinued operations | (371) | (317) |
Effect of exchange rate changes on cash and cash equivalents | (6,330) | 885 |
Net (decrease) increase in cash and cash equivalents | (14,099) | 252,452 |
Cash and cash equivalents at the beginning of the period | 375,880 | 301,083 |
Cash and cash equivalents at the end of the period | $ 361,781 | $ 553,535 |
CONDENSED CONSOLIDATED STATEM_5
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands | Total | Cumulative Effect, Period of Adoption, Adjustment | Common Stock | Additional Paid In Capital | Retained Earnings | Retained EarningsCumulative Effect, Period of Adoption, Adjustment | Accumulated Other Comprehensive Loss | Treasury Stock |
Beginning Balance (in shares) at Dec. 31, 2019 | 47,536 | 1,182 | ||||||
Beginning Balance at Dec. 31, 2019 | $ 2,979,320 | $ (791) | $ 47,536 | $ 616,980 | $ 2,824,916 | $ (791) | $ (344,392) | $ (165,720) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 131,150 | 131,150 | ||||||
Cash dividends | (15,767) | (15,767) | ||||||
Other comprehensive loss | (20,327) | (20,327) | ||||||
Shares issued under compensation plans (in shares) | 24 | (37) | ||||||
Shares issued under compensation plans | (1,302) | $ 24 | (3,074) | $ 1,748 | ||||
Deferred compensation (in shares) | (5) | |||||||
Deferred compensation | 741 | 383 | $ 358 | |||||
Ending Balance (in shares) at Mar. 29, 2020 | 47,560 | 1,140 | ||||||
Ending Balance at Mar. 29, 2020 | 3,073,024 | $ 47,560 | 614,289 | 2,939,508 | (364,719) | $ (163,614) | ||
Beginning Balance (in shares) at Dec. 31, 2019 | 47,536 | 1,182 | ||||||
Beginning Balance at Dec. 31, 2019 | 2,979,320 | $ (791) | $ 47,536 | 616,980 | 2,824,916 | $ (791) | (344,392) | $ (165,720) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 142,606 | |||||||
Other comprehensive loss | (2,423) | |||||||
Ending Balance (in shares) at Jun. 28, 2020 | 47,595 | 1,136 | ||||||
Ending Balance at Jun. 28, 2020 | 3,097,402 | $ 47,595 | 624,805 | 2,935,173 | (346,815) | $ (163,356) | ||
Beginning Balance (in shares) at Mar. 29, 2020 | 47,560 | 1,140 | ||||||
Beginning Balance at Mar. 29, 2020 | 3,073,024 | $ 47,560 | 614,289 | 2,939,508 | (364,719) | $ (163,614) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 11,456 | 11,456 | ||||||
Cash dividends | (15,791) | (15,791) | ||||||
Other comprehensive loss | 17,904 | 17,904 | ||||||
Shares issued under compensation plans (in shares) | 35 | (3) | ||||||
Shares issued under compensation plans | 10,726 | $ 35 | 10,516 | $ 175 | ||||
Deferred compensation (in shares) | (1) | |||||||
Deferred compensation | 83 | 0 | $ 83 | |||||
Ending Balance (in shares) at Jun. 28, 2020 | 47,595 | 1,136 | ||||||
Ending Balance at Jun. 28, 2020 | 3,097,402 | $ 47,595 | 624,805 | 2,935,173 | (346,815) | $ (163,356) | ||
Beginning Balance (in shares) at Dec. 31, 2020 | 47,812 | 1,132 | ||||||
Beginning Balance at Dec. 31, 2020 | 3,336,457 | $ 47,812 | 652,305 | 3,096,228 | (297,298) | $ (162,590) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 74,866 | 74,866 | ||||||
Cash dividends | (15,893) | (15,893) | ||||||
Other comprehensive loss | (22,437) | (22,437) | ||||||
Shares issued under compensation plans (in shares) | 18 | (28) | ||||||
Shares issued under compensation plans | 2,110 | $ 18 | 1,993 | $ 99 | ||||
Deferred compensation (in shares) | (4) | |||||||
Deferred compensation | 688 | 447 | $ 241 | |||||
Ending Balance (in shares) at Mar. 28, 2021 | 47,830 | 1,100 | ||||||
Ending Balance at Mar. 28, 2021 | 3,375,791 | $ 47,830 | 654,745 | 3,155,201 | (319,735) | $ (162,250) | ||
Beginning Balance (in shares) at Dec. 31, 2020 | 47,812 | 1,132 | ||||||
Beginning Balance at Dec. 31, 2020 | 3,336,457 | $ 47,812 | 652,305 | 3,096,228 | (297,298) | $ (162,590) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 158,114 | |||||||
Other comprehensive loss | (14,662) | |||||||
Ending Balance (in shares) at Jun. 27, 2021 | 47,882 | 1,099 | ||||||
Ending Balance at Jun. 27, 2021 | 3,466,102 | $ 47,882 | 669,877 | 3,222,549 | (311,960) | $ (162,246) | ||
Beginning Balance (in shares) at Mar. 28, 2021 | 47,830 | 1,100 | ||||||
Beginning Balance at Mar. 28, 2021 | 3,375,791 | $ 47,830 | 654,745 | 3,155,201 | (319,735) | $ (162,250) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 83,248 | 83,248 | ||||||
Cash dividends | (15,900) | (15,900) | ||||||
Other comprehensive loss | 7,775 | 7,775 | ||||||
Shares issued under compensation plans (in shares) | 52 | (1) | ||||||
Shares issued under compensation plans | 15,200 | $ 52 | 15,132 | $ 16 | ||||
Deferred compensation (in shares) | 0 | |||||||
Deferred compensation | (12) | 0 | $ (12) | |||||
Ending Balance (in shares) at Jun. 27, 2021 | 47,882 | 1,099 | ||||||
Ending Balance at Jun. 27, 2021 | $ 3,466,102 | $ 47,882 | $ 669,877 | $ 3,222,549 | $ (311,960) | $ (162,246) |
CONDENSED CONSOLIDATED STATEM_6
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares | 3 Months Ended | |||
Jun. 27, 2021 | Mar. 28, 2021 | Jun. 28, 2020 | Mar. 29, 2020 | |
Statement of Stockholders' Equity [Abstract] | ||||
Dividends per share (in dollars per share) | $ 0.34 | $ 0.34 | $ 0.34 | $ 0.34 |
Basis of presentation
Basis of presentation | 6 Months Ended |
Jun. 27, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of presentation | Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. |
Recently issued accounting stan
Recently issued accounting standards | 6 Months Ended |
Jun. 27, 2021 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
Recently issued accounting standards | Recently issued accounting standards In December 2019, the FASB issued new guidance that simplifies various aspects of accounting for income taxes including those related to the step-up in the tax basis of goodwill, intraperiod tax allocations and the interim period effects of changes in tax laws or rates. The new guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The modifications under the new guidance were applied on a prospective basis effective January 1, 2021. The adoption of the new guidance did not have a material effect on the condensed consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position. |
Net revenues
Net revenues | 6 Months Ended |
Jun. 27, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Net revenues | Net revenuesWe primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For our Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which comprised 89%, 9% and 2% of consolidated net revenues, respectively, for the six months ended June 27, 2021. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. The following table disaggregates revenue by global product category for the three and six months ended June 27, 2021 and June 28, 2020. Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Vascular access $ 167,739 $ 164,958 $ 331,712 $ 315,214 Anesthesia 95,426 64,867 180,283 140,569 Interventional 112,082 82,594 208,255 182,525 Surgical 98,185 67,275 178,571 142,707 Interventional urology 92,243 40,094 165,607 114,286 OEM 60,956 55,832 114,445 119,219 Other (1) 86,842 91,414 168,525 183,156 Net revenues (2) $ 713,473 $ 567,034 $ 1,347,398 $ 1,197,676 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). (2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments include net revenues from each of the non-OEM product categories listed above. |
Acquisitions and Divestitures
Acquisitions and Divestitures | 6 Months Ended |
Jun. 27, 2021 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions and Divestitures | Acquisitions and divestitures Acquisitions On February 18, 2020, we acquired IWG High Performance Conductors, Inc. ("HPC"), a privately-held original equipment manufacturer of minimally invasive medical products and high performance conductors. The acquisition complements our OEM product portfolio. On December 28, 2020, we acquired Z-Medica, LLC ("Z-Medica"), a privately-held medical device company that manufactures and sells hemostatic (hemorrhage control) products, marketed under the QuikClot, Combat Gauze and QuickClot Control+ brand names, to complement our anesthesia product portfolio. The acquisition included an initial cash purchase price of $500.0 million, with the potential to make an additional payment up to $25 million upon the achievement of certain commercial milestones. Divestiture On May 15, 2021, we entered into a definitive agreement to sell certain product lines within our global respiratory product portfolio (the "Divested respiratory business") to Medline Industries, Inc. (“Medline”) for consideration of $286.0 million, reduced by $12 million in working capital not transferring to Medline, and is subject to customary post-close adjustments (the "Respiratory business divestiture"). On June 28, 2021, the first day of the third quarter of 2021, we completed the initial phase of the Respiratory business divestiture, pursuant to which we received cash proceeds of $259 million and we estimate that we will recognize a pre-tax gain on the sale of approximately $100 million. The second phase of the divestiture will occur once we transfer certain additional manufacturing assets to Medline. Our receipt of $15.0 million in additional cash proceeds is contingent upon the transfer of these manufacturing assets and is expected to occur prior to the end of 2023. We plan to recognize the contingent consideration, and any gain on sale resulting from the second phase of the divestiture, when it becomes realizable. In connection with the Respiratory business divestiture, we entered into several ancillary agreements with Medline to help facilitate the transfer of the business, which provide for transition support, quality, supply and manufacturing services. Net sales attributable to our Divested respiratory business are included within each of our geographic segments and were $29.6 million and $60.7 million during the three and six months ended June 27, 2021, respectively, and $138.5 million during the year ended December 31, 2020. As a result of the Respiratory business divestiture, the following assets and liabilities were designated as assets and liabilities held for sale as of June 27, 2021: June 27, 2021 Assets Inventories $ 26,936 Current assets held-for-sale 26,936 Property, plant and equipment, net 17,006 Intangible assets, net 41,583 Goodwill 35,745 Operating lease assets 1,053 Other assets 39 Noncurrent assets held-for-sale 95,426 Total assets held-for-sale $ 122,362 Liabilities Other current liabilities $ 488 Noncurrent operating lease liabilities 568 Liabilities held-for-sale $ 1,056 |
Restructuring and impairment ch
Restructuring and impairment charges | 6 Months Ended |
Jun. 27, 2021 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and impairment charges | Restructuring and impairment charges Respiratory divestiture plan During the second quarter of 2021, in connection with the Respiratory business divestiture described in Note 4, we committed to a restructuring plan designed to separate the manufacturing operations that will be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites that will be transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan: Total estimated amount expected to be incurred Program expense estimates: (Dollars in millions) Restructuring charges (1) $5 million to $8 million Restructuring related charges (2) $19 million to $22 million Total restructuring and restructuring related charges $24 million to $30 million (1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold. We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays, the majority of which will be made in 2022 and 2023. Additionally, we expect to incur $22 million to $28 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2022 and 2023. As of June 27, 2021, we had a restructuring reserve of $2.5 million related to this plan, all of which related to termination benefits. 2021 Restructuring plan During the first quarter of 2021, we committed to a restructuring plan designed to streamline various business functions across our segments. We estimate that we will incur aggregate pre-tax restructuring charges of $7 million to $9 million, consisting primarily of termination benefits. In addition, we expect to incur $3 million to $4 million in restructuring related charges, most of which are expected to be recognized in cost of goods sold. We expect this plan will be substantially completed by the end of 2021. As of June 27, 2021, we had a restructuring reserve of $5.1 million related to this plan, all of which related to termination benefits. Footprint realignment plans We have ongoing restructuring programs related to the relocation of manufacturing operations to existing lower-cost locations and related workforce reductions (referred to as the 2019, 2018 and 2014 Footprint realignment plans). The following tables provide a summary of our cost estimates and other information associated with these ongoing Footprint realignment plans: 2019 Footprint realignment plan 2018 Footprint realignment plan 2014 Footprint realignment plan Program expense estimates: (Dollars in millions) Termination benefits $14 to $16 $60 to $70 $13 to $13 Other costs (1) 2 to 2 3 to 4 1 to 2 Restructuring charges 16 to 18 63 to 74 14 to 15 Restructuring related charges (2) 38 to 43 40 to 59 38 to 40 Total restructuring and restructuring related charges $54 to $61 $103 to $133 $52 to $55 Other program estimates: Expected cash outlays $48 to $55 $99 to $127 $42 to $46 Expected capital expenditures $28 to $33 $19 to $23 $26 to $27 Other program information: Period initiated February 2019 May 2018 April 2014 Estimated period of substantial completion 2022 2022 2022 Aggregate restructuring charges $15.5 $61.9 $13.7 Restructuring reserve: Balance as of June 27, 2021 $5.4 $47.2 $3.1 Restructuring related charges incurred: Three Months Ended June 27, 2021 $3.9 $2.3 $1.0 Six Months Ended June 27, 2021 $7.4 $4.3 $1.7 Aggregate restructuring related charges $28.6 $21.0 $37.7 (1) Includes facility closure, employee relocation, equipment relocation and outplacement costs. (2) Restructuring related charges represent costs that are directly related to the programs and principally constitute costs to transfer manufacturing operations to the existing lower-cost locations, project management costs and accelerated depreciation. The 2018 Footprint realignment plan also includes a charge associated with our exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the restructuring related charges are expected to be recognized within cost of goods sold. Restructuring and impairment charges recognized for the three and six months ended June 27, 2021 and June 28, 2020 consisted of the following: Three Months Ended June 27, 2021 Termination benefits Other costs (1) Total Respiratory divestiture plan $ 2,540 $ 1 $ 2,541 2021 Restructuring plan 129 23 152 2019 Footprint realignment plan (301) 91 (210) 2018 Footprint realignment plan 1,459 92 1,551 Other restructuring programs (2) (4) 725 721 Restructuring charges 3,823 932 4,755 Asset impairment charges — 6,739 6,739 Restructuring and impairment charges $ 3,823 $ 7,671 $ 11,494 Three Months Ended June 28, 2020 Termination benefits Other costs (1) Total 2020 Workforce reduction plan $ 10,564 $ — $ 10,564 2019 Footprint realignment plan 323 82 405 2018 Footprint realignment plan 7,545 52 7,597 Other restructuring programs (2) 169 270 439 Restructuring charges $ 18,601 $ 404 $ 19,005 Six Months Ended June 27, 2021 Termination benefits Other costs (1) Total Respiratory divestiture plan $ 2,540 $ 1 $ 2,541 2021 Restructuring plan 6,889 23 6,912 2019 Footprint realignment plan 40 196 236 2018 Footprint realignment plan 1,726 137 1,863 Other restructuring programs (2) (170) 1,371 1,201 Restructuring charges 11,025 1,728 12,753 Asset impairment charges — 6,739 6,739 Restructuring and impairment charges $ 11,025 $ 8,467 $ 19,492 Six Months Ended June 28, 2020 Termination benefits Other costs (1) Total 2020 Workforce reduction plan $ 10,564 $ — $ 10,564 2019 Footprint realignment plan 1,152 91 1,243 2018 Footprint realignment plan 7,859 133 7,992 Other restructuring programs (2) 62 490 552 Restructuring charges $ 19,637 $ 714 $ 20,351 (1) Other costs include facility closure, contract termination and other exit costs. (2) Includes the program initiated during third quarter of 2019 as well as the 2016 and 2014 Footprint realignment plans. Impairment Charges |
Inventories
Inventories | 6 Months Ended |
Jun. 27, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories Inventories as of June 27, 2021 and December 31, 2020 consisted of the following: June 27, 2021 December 31, 2020 Raw materials $ 133,722 $ 132,370 Work-in-process 78,088 75,874 Finished goods 278,508 304,952 Inventories $ 490,318 $ 513,196 |
Goodwill and other intangible a
Goodwill and other intangible assets | 6 Months Ended |
Jun. 27, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and other intangible assets | Goodwill and other intangible assets The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the six months ended June 27, 2021: Americas EMEA Asia OEM Total December 31, 2020 $ 1,700,282 $ 536,228 $ 237,446 $ 112,010 $ 2,585,966 Goodwill held-for-sale (21,802) (7,537) (6,406) — (35,745) Currency translation adjustment 1,081 (9,507) (4,363) — (12,789) June 27, 2021 $ 1,679,561 $ 519,184 $ 226,677 $ 112,010 $ 2,537,432 The gross carrying amount of, and accumulated amortization relating to, intangible assets as of June 27, 2021 and December 31, 2020 were as follows: Gross Carrying Amount Accumulated Amortization June 27, 2021 December 31, 2020 June 27, 2021 December 31, 2020 Customer relationships $ 1,335,685 $ 1,377,943 $ (414,086) $ (425,692) In-process research and development 29,136 29,627 — — Intellectual property 1,444,105 1,458,924 (519,239) (479,612) Distribution rights 23,722 23,866 (20,525) (20,280) Trade names 555,192 619,847 (53,519) (65,955) Non-compete agreements 24,002 24,592 (23,144) (23,514) $ 3,411,842 $ 3,534,799 $ (1,030,513) $ (1,015,053) |
Borrowings
Borrowings | 6 Months Ended |
Jun. 27, 2021 | |
Debt Disclosure [Abstract] | |
Borrowings | Borrowings Our borrowings at June 27, 2021 and December 31, 2020 were as follows: June 27, 2021 December 31, 2020 Senior Credit Facility: Revolving credit facility, at a rate of 1.59% at June 27, 2021, due 2024 $ 600,500 $ 350,000 Term loan facility, at a rate of 1.59% at June 27, 2021, due 2024 647,500 673,000 4.875% Senior Notes due 2026 — 400,000 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 1.20% at June 27, 2021 75,000 75,000 2,323,000 2,498,000 Less: Unamortized debt issuance costs (14,834) (19,612) 2,308,166 2,478,388 Current borrowings (92,500) (100,500) Long-term borrowings $ 2,215,666 $ 2,377,888 Redemption of 4.875% Senior Notes due 2026 On April 29, 2021, we issued a notice of redemption to holders of our outstanding $400 million aggregate principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”). Pursuant to the notice of redemption, the 2026 Notes were redeemed on June 1, 2021 (the “Redemption Date”) at a redemption price equal to 102.438% of the principal amount of the 2026 Notes plus accrued and unpaid interest up to, but not including, the Redemption Date (the “Redemption Price”). We recognized a loss on extinguishment of debt of $13.0 million as a result of the redemption of the 2026 Notes. Subsequent event On July 6, 2021, we repaid $259 million in borrowings under our revolving credit facility using funds primarily consisting of proceeds we received from the initial close of the Respiratory business divestiture described in Note 4. |
Financial instruments
Financial instruments | 6 Months Ended |
Jun. 27, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Financial instruments | Financial instruments Foreign currency forward contracts We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We enter into the non-designated foreign currency forward contracts for periods consistent with our currency translation exposures, which generally approximate one month. For the three and six months ended June 27, 2021 we recognized a gain of $0.7 million and a loss of $2.5 million, respectively, related to non-designated foreign currency forward contracts. For the three and six months ended June 28, 2020 we recognized a loss of $0.8 million and a gain of $0.8 million, respectively, related to non-designated foreign currency forward contracts. The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of June 27, 2021 and December 31, 2020 was $137.0 million and $129.5 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of June 27, 2021 and December 31, 2020 was $189.2 million and $163.5 million, respectively. All open foreign currency forward contracts as of June 27, 2021 have durations of 12 months or less. Cross-currency interest rate swaps During 2019, we entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $250 million at an annual interest rate of 4.875% for €219.2 million at an annual interest rate of 2.4595%. The swap agreements are designed as net investment hedges and expire on March 4, 2024. During 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designed as net investment hedges and expire on October 4, 2023. The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and six months ended June 27, 2021 and June 28, 2020: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Foreign exchange (losses) gains $ (7,127) $ (7,408) $ 10,487 $ 17,607 Interest benefit 4,479 4,931 9,126 9,805 Balance sheet presentation The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of June 27, 2021 and December 31, 2020: June 27, 2021 December 31, 2020 Asset derivatives: Designated foreign currency forward contracts $ 1,199 $ 1,691 Non-designated foreign currency forward contracts 73 61 Cross-currency interest rate swaps 20,633 20,106 Prepaid expenses and other current assets 21,905 21,858 Total asset derivatives $ 21,905 $ 21,858 Liability derivatives: Designated foreign currency forward contracts $ 1,372 $ 1,504 Non-designated foreign currency forward contracts 430 366 Other current liabilities 1,802 1,870 Cross-currency interest rate swaps 21,183 34,125 Other liabilities 21,183 34,125 Total liability derivatives $ 22,985 $ 35,995 See Note 11 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. There was no ineffectiveness related to our cash flow hedges during the three and six months ended June 27, 2021 and June 28, 2020. |
Fair value measurement
Fair value measurement | 6 Months Ended |
Jun. 27, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair value measurement | Fair value measurement The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of June 27, 2021 and December 31, 2020: Total carrying value at June 27, 2021 Quoted prices in active Significant other Significant Investments in marketable securities $ 14,287 $ 14,287 $ — $ — Derivative assets 21,905 — 21,905 — Derivative liabilities 22,985 — 22,985 — Contingent consideration liabilities 13,974 — — 13,974 Total carrying Quoted prices in active Significant other Significant Investments in marketable securities $ 12,617 $ 12,617 $ — $ — Derivative assets 21,858 — 21,858 — Derivative liabilities 35,995 — 35,995 — Contingent consideration liabilities 36,633 — — 36,633 Valuation Techniques Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under our benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forwards and cross-currency interest rate swaps to manage foreign currency transaction exposure, as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forwards and cross-currency swaps by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. Our financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to our acquisitions, which are discussed immediately below. Contingent consideration Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration. Contingent Consideration Liability Valuation Technique Unobservable Input Range (Weighted average) Milestone-based payments Discounted cash flow Discount rate 1.2% - 2.5% (1.9%) Projected year of payment 2021 - 2023 Revenue-based payments Discounted cash flow Discount rate 1.3% - 10.0% (4.4%) Projected year of payment 2021 - 2029 The following table provides information regarding changes in the contingent consideration liabilities during the six months ended June 27, 2021: Contingent consideration Balance - December 31, 2020 $ 36,633 Payments (1) (30,489) Revaluations and other adjustments 7,848 Translation adjustments (18) Balance - June 27, 2021 $ 13,974 (1) Includes $17.4 million payment associated with a settlement reached with the shareholders from whom we acquired Essential Medical, Inc. See Note 13 for additional information related to the settlement. |
Shareholders' equity
Shareholders' equity | 6 Months Ended |
Jun. 27, 2021 | |
Equity [Abstract] | |
Shareholders' equity | Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Basic 46,741 46,442 46,719 46,412 Dilutive effect of share-based awards 692 800 701 825 Diluted 47,433 47,242 47,420 47,237 The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.1 million for the three and six months ended June 27, 2021, and 0.2 million and 0.1 million for the three and six months ended June 28, 2020, respectively. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended June 27, 2021 and June 28, 2020: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income Balance as of December 31, 2020 $ (482) $ (150,257) $ (146,559) $ (297,298) Other comprehensive (loss) income before reclassifications (574) 9 (17,995) (18,560) Amounts reclassified from accumulated other comprehensive income 998 2,900 — 3,898 Net current-period other comprehensive income (loss) 424 2,909 (17,995) (14,662) Balance as of June 27, 2021 $ (58) $ (147,348) $ (164,554) $ (311,960) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income Balance as of December 31, 2019 $ 735 $ (138,810) $ (206,317) $ (344,392) Other comprehensive (loss) income before reclassifications (4,189) 183 (545) (4,551) Amounts reclassified from accumulated other comprehensive loss (723) 2,851 — 2,128 Net current-period other comprehensive (loss) income (4,912) 3,034 (545) (2,423) Balance as of June 28, 2020 $ (4,177) $ (135,776) $ (206,862) $ (346,815) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended June 27, 2021 and June 28, 2020: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Losses (gains) on foreign exchange contracts: Cost of goods sold $ 133 $ (685) $ 979 $ (751) Total before tax 133 (685) 979 (751) Taxes 27 19 19 28 Net of tax $ 160 $ (666) $ 998 $ (723) Amortization of pension and other postretirement benefit items (1) : Actuarial losses $ 2,144 $ 1,850 $ 4,287 $ 3,702 Prior-service costs (251) 8 (502) 16 Total before tax 1,893 1,858 3,785 3,718 Tax benefit (443) (433) (885) (867) Net of tax $ 1,450 $ 1,425 $ 2,900 $ 2,851 Total reclassifications, net of tax $ 1,610 $ 759 $ 3,898 $ 2,128 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans. |
Taxes on income from continuing
Taxes on income from continuing operations | 6 Months Ended |
Jun. 27, 2021 | |
Income Tax Disclosure [Abstract] | |
Taxes on income from continuing operations | Taxes on income from continuing operations Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Effective income tax rate 16.5% 50.9% 15.4% 13.8% |
Commitments and contingent liab
Commitments and contingent liabilities | 6 Months Ended |
Jun. 27, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingent liabilities | Commitments and contingent liabilities Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At June 27, 2021, we have recorded $1.6 million and $4.9 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of June 27, 2021. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years. Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of June 27, 2021, we have recorded accrued liabilities of $0.4 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. As previously disclosed, in the first quarter of 2021, representatives of the selling shareholders from whom we acquired Essential Medical, Inc., filed suit on behalf of such shareholders in the Court of Chancery of the State of Delaware alleging, among other things, that we breached the merger agreement relating to the acquisition in connection with activities relating to the achievement of revenue-based milestone goals under the agreement. The suit sought money damages in the amount of $66.9 million, plus interest. During the second quarter of 2021, the parties entered into a settlement agreement, pursuant to which we paid $17.4 million to the selling shareholders, the selling shareholders released us from the claims asserted in the lawsuit as well as any remaining obligations to make milestone payments and any other obligations relating to the merger agreement, and the lawsuit was dismissed with prejudice. As a result, we have no further potential liability related to this matter. In June 2020, we began producing documents and information in response to a Civil Investigative Demand (a “CID”) received in March 2020 by one of our subsidiaries, NeoTract, Inc. (“NeoTract”), from the U.S. Department of Justice through the United States Attorney’s Office for the Northern District of Georgia (collectively, the “DOJ”). The CID relates to the DOJ’s investigation of a single NeoTract customer, requires the production of documents and information pertaining to communications with, and certain rebate programs offered to, that customer and pertains to communications and activities occurring both prior to our acquisition of NeoTract in October 2017 and thereafter. In July 2020, the DOJ advised us that it had opened an investigation under the civil False Claims Act, 31 U.S.C. §3729, with respect to NeoTract’s operations broadly in addition to the customer investigation. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. We maintain policies and procedures to promote compliance with the Anti-Kickback Statute, False Claims Acts and other applicable laws and regulations and intend to provide information sought by the government. We cannot at this time reasonably predict, however, the ultimate scope or outcome of this matter, including whether an investigation may raise other compliance issues of interest, including those beyond the scope described above or how any such issues might be resolved. We also cannot at this time reasonably estimate any potential liabilities or penalty, if any, that may arise from this matter, which could have a material adverse effect on our results of operations and financial condition. Tax audits and examinations: We are routinely subject to tax examinations by various tax authorities. As of June 27, 2021, the most significant tax examinations in process were in Ireland and Germany. We may establish |
Segment information
Segment information | 6 Months Ended |
Jun. 27, 2021 | |
Segment Reporting [Abstract] | |
Segment information | Segment information The following tables present our segment results for the three and six months ended June 27, 2021 and June 28, 2020: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Americas $ 414,785 $ 312,490 $ 790,278 $ 670,492 EMEA 157,129 131,643 298,382 287,767 Asia 80,603 67,069 144,293 120,198 OEM 60,956 55,832 114,445 119,219 Net revenues $ 713,473 $ 567,034 $ 1,347,398 $ 1,197,676 Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Americas $ 105,379 $ 47,539 $ 188,981 $ 188,507 EMEA 23,301 14,923 46,296 35,342 Asia 23,188 13,626 38,104 23,858 OEM 15,262 12,244 27,824 27,343 Total segment operating profit (1) 167,130 88,332 301,205 275,050 Unallocated expenses (2) (38,510) (49,522) (69,151) (79,154) Income from continuing operations before interest and taxes $ 128,620 $ 38,810 $ 232,054 $ 195,896 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of assets. |
Recently issued accounting st_2
Recently issued accounting standards (Policies) | 6 Months Ended |
Jun. 27, 2021 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
Basis of presentation | Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. |
Recently issued accounting standards | Recently issued accounting standards In December 2019, the FASB issued new guidance that simplifies various aspects of accounting for income taxes including those related to the step-up in the tax basis of goodwill, intraperiod tax allocations and the interim period effects of changes in tax laws or rates. The new guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The modifications under the new guidance were applied on a prospective basis effective January 1, 2021. The adoption of the new guidance did not have a material effect on the condensed consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position. |
Net revenues (Tables)
Net revenues (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Revenue by Major Customers by Reporting Segments | The following table disaggregates revenue by global product category for the three and six months ended June 27, 2021 and June 28, 2020. Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Vascular access $ 167,739 $ 164,958 $ 331,712 $ 315,214 Anesthesia 95,426 64,867 180,283 140,569 Interventional 112,082 82,594 208,255 182,525 Surgical 98,185 67,275 178,571 142,707 Interventional urology 92,243 40,094 165,607 114,286 OEM 60,956 55,832 114,445 119,219 Other (1) 86,842 91,414 168,525 183,156 Net revenues (2) $ 713,473 $ 567,034 $ 1,347,398 $ 1,197,676 (1) Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products). (2) The product categories listed above are presented on a global basis, while each of our reportable segments other than the OEM reportable segment are defined based on the geographic location of its operations; the OEM reportable segment operates globally. Each of the geographically based reportable segments include net revenues from each of the non-OEM product categories listed above. |
Acquisitions and Divestitures (
Acquisitions and Divestitures (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Business Combination and Asset Acquisition [Abstract] | |
Disposal Groups, Including Discontinued Operations | As a result of the Respiratory business divestiture, the following assets and liabilities were designated as assets and liabilities held for sale as of June 27, 2021: June 27, 2021 Assets Inventories $ 26,936 Current assets held-for-sale 26,936 Property, plant and equipment, net 17,006 Intangible assets, net 41,583 Goodwill 35,745 Operating lease assets 1,053 Other assets 39 Noncurrent assets held-for-sale 95,426 Total assets held-for-sale $ 122,362 Liabilities Other current liabilities $ 488 Noncurrent operating lease liabilities 568 Liabilities held-for-sale $ 1,056 |
Restructuring and impairment _2
Restructuring and impairment charges (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Restructuring and Related Activities [Abstract] | |
Summary Of Current Cost Estimates By Major Type Of Cost Table | The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan: Total estimated amount expected to be incurred Program expense estimates: (Dollars in millions) Restructuring charges (1) $5 million to $8 million Restructuring related charges (2) $19 million to $22 million Total restructuring and restructuring related charges $24 million to $30 million (1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold. 2019 Footprint realignment plan 2018 Footprint realignment plan 2014 Footprint realignment plan Program expense estimates: (Dollars in millions) Termination benefits $14 to $16 $60 to $70 $13 to $13 Other costs (1) 2 to 2 3 to 4 1 to 2 Restructuring charges 16 to 18 63 to 74 14 to 15 Restructuring related charges (2) 38 to 43 40 to 59 38 to 40 Total restructuring and restructuring related charges $54 to $61 $103 to $133 $52 to $55 Other program estimates: Expected cash outlays $48 to $55 $99 to $127 $42 to $46 Expected capital expenditures $28 to $33 $19 to $23 $26 to $27 Other program information: Period initiated February 2019 May 2018 April 2014 Estimated period of substantial completion 2022 2022 2022 Aggregate restructuring charges $15.5 $61.9 $13.7 Restructuring reserve: Balance as of June 27, 2021 $5.4 $47.2 $3.1 Restructuring related charges incurred: Three Months Ended June 27, 2021 $3.9 $2.3 $1.0 Six Months Ended June 27, 2021 $7.4 $4.3 $1.7 Aggregate restructuring related charges $28.6 $21.0 $37.7 (1) Includes facility closure, employee relocation, equipment relocation and outplacement costs. |
Restructuring and Other Impairment Charges | Restructuring and impairment charges recognized for the three and six months ended June 27, 2021 and June 28, 2020 consisted of the following: Three Months Ended June 27, 2021 Termination benefits Other costs (1) Total Respiratory divestiture plan $ 2,540 $ 1 $ 2,541 2021 Restructuring plan 129 23 152 2019 Footprint realignment plan (301) 91 (210) 2018 Footprint realignment plan 1,459 92 1,551 Other restructuring programs (2) (4) 725 721 Restructuring charges 3,823 932 4,755 Asset impairment charges — 6,739 6,739 Restructuring and impairment charges $ 3,823 $ 7,671 $ 11,494 Three Months Ended June 28, 2020 Termination benefits Other costs (1) Total 2020 Workforce reduction plan $ 10,564 $ — $ 10,564 2019 Footprint realignment plan 323 82 405 2018 Footprint realignment plan 7,545 52 7,597 Other restructuring programs (2) 169 270 439 Restructuring charges $ 18,601 $ 404 $ 19,005 Six Months Ended June 27, 2021 Termination benefits Other costs (1) Total Respiratory divestiture plan $ 2,540 $ 1 $ 2,541 2021 Restructuring plan 6,889 23 6,912 2019 Footprint realignment plan 40 196 236 2018 Footprint realignment plan 1,726 137 1,863 Other restructuring programs (2) (170) 1,371 1,201 Restructuring charges 11,025 1,728 12,753 Asset impairment charges — 6,739 6,739 Restructuring and impairment charges $ 11,025 $ 8,467 $ 19,492 Six Months Ended June 28, 2020 Termination benefits Other costs (1) Total 2020 Workforce reduction plan $ 10,564 $ — $ 10,564 2019 Footprint realignment plan 1,152 91 1,243 2018 Footprint realignment plan 7,859 133 7,992 Other restructuring programs (2) 62 490 552 Restructuring charges $ 19,637 $ 714 $ 20,351 (1) Other costs include facility closure, contract termination and other exit costs. (2) Includes the program initiated during third quarter of 2019 as well as the 2016 and 2014 Footprint realignment plans. |
Inventories (Tables)
Inventories (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventories as of June 27, 2021 and December 31, 2020 consisted of the following: June 27, 2021 December 31, 2020 Raw materials $ 133,722 $ 132,370 Work-in-process 78,088 75,874 Finished goods 278,508 304,952 Inventories $ 490,318 $ 513,196 |
Goodwill and other intangible_2
Goodwill and other intangible assets, net (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the six months ended June 27, 2021: Americas EMEA Asia OEM Total December 31, 2020 $ 1,700,282 $ 536,228 $ 237,446 $ 112,010 $ 2,585,966 Goodwill held-for-sale (21,802) (7,537) (6,406) — (35,745) Currency translation adjustment 1,081 (9,507) (4,363) — (12,789) June 27, 2021 $ 1,679,561 $ 519,184 $ 226,677 $ 112,010 $ 2,537,432 |
Schedule of Finite-Lived Intangible Assets | The gross carrying amount of, and accumulated amortization relating to, intangible assets as of June 27, 2021 and December 31, 2020 were as follows: Gross Carrying Amount Accumulated Amortization June 27, 2021 December 31, 2020 June 27, 2021 December 31, 2020 Customer relationships $ 1,335,685 $ 1,377,943 $ (414,086) $ (425,692) In-process research and development 29,136 29,627 — — Intellectual property 1,444,105 1,458,924 (519,239) (479,612) Distribution rights 23,722 23,866 (20,525) (20,280) Trade names 555,192 619,847 (53,519) (65,955) Non-compete agreements 24,002 24,592 (23,144) (23,514) $ 3,411,842 $ 3,534,799 $ (1,030,513) $ (1,015,053) |
Borrowings (Tables)
Borrowings (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Debt Disclosure [Abstract] | |
Components of Long-Term Debt | Our borrowings at June 27, 2021 and December 31, 2020 were as follows: June 27, 2021 December 31, 2020 Senior Credit Facility: Revolving credit facility, at a rate of 1.59% at June 27, 2021, due 2024 $ 600,500 $ 350,000 Term loan facility, at a rate of 1.59% at June 27, 2021, due 2024 647,500 673,000 4.875% Senior Notes due 2026 — 400,000 4.625% Senior Notes due 2027 500,000 500,000 4.25% Senior Notes due 2028 500,000 500,000 Securitization program, at a rate of 1.20% at June 27, 2021 75,000 75,000 2,323,000 2,498,000 Less: Unamortized debt issuance costs (14,834) (19,612) 2,308,166 2,478,388 Current borrowings (92,500) (100,500) Long-term borrowings $ 2,215,666 $ 2,377,888 |
Financial instruments (Tables)
Financial instruments (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Fair Values of Derivative Instruments Designated as Hedging Instruments | The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of June 27, 2021 and December 31, 2020: June 27, 2021 December 31, 2020 Asset derivatives: Designated foreign currency forward contracts $ 1,199 $ 1,691 Non-designated foreign currency forward contracts 73 61 Cross-currency interest rate swaps 20,633 20,106 Prepaid expenses and other current assets 21,905 21,858 Total asset derivatives $ 21,905 $ 21,858 Liability derivatives: Designated foreign currency forward contracts $ 1,372 $ 1,504 Non-designated foreign currency forward contracts 430 366 Other current liabilities 1,802 1,870 Cross-currency interest rate swaps 21,183 34,125 Other liabilities 21,183 34,125 Total liability derivatives $ 22,985 $ 35,995 |
Schedule of foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense | The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swap for the three and six months ended June 27, 2021 and June 28, 2020: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Foreign exchange (losses) gains $ (7,127) $ (7,408) $ 10,487 $ 17,607 Interest benefit 4,479 4,931 9,126 9,805 |
Fair value measurement (Tables)
Fair value measurement (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Fair Value Disclosures [Abstract] | |
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis | The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of June 27, 2021 and December 31, 2020: Total carrying value at June 27, 2021 Quoted prices in active Significant other Significant Investments in marketable securities $ 14,287 $ 14,287 $ — $ — Derivative assets 21,905 — 21,905 — Derivative liabilities 22,985 — 22,985 — Contingent consideration liabilities 13,974 — — 13,974 Total carrying Quoted prices in active Significant other Significant Investments in marketable securities $ 12,617 $ 12,617 $ — $ — Derivative assets 21,858 — 21,858 — Derivative liabilities 35,995 — 35,995 — Contingent consideration liabilities 36,633 — — 36,633 |
Schedule of Valuation Techniques | The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration. Contingent Consideration Liability Valuation Technique Unobservable Input Range (Weighted average) Milestone-based payments Discounted cash flow Discount rate 1.2% - 2.5% (1.9%) Projected year of payment 2021 - 2023 Revenue-based payments Discounted cash flow Discount rate 1.3% - 10.0% (4.4%) Projected year of payment 2021 - 2029 |
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis | The following table provides information regarding changes in the contingent consideration liabilities during the six months ended June 27, 2021: Contingent consideration Balance - December 31, 2020 $ 36,633 Payments (1) (30,489) Revaluations and other adjustments 7,848 Translation adjustments (18) Balance - June 27, 2021 $ 13,974 (1) Includes $17.4 million payment associated with a settlement reached with the shareholders from whom we acquired Essential Medical, Inc. See Note 13 for additional information related to the settlement. |
Shareholders' equity (Tables)
Shareholders' equity (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Equity [Abstract] | |
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding | The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Basic 46,741 46,442 46,719 46,412 Dilutive effect of share-based awards 692 800 701 825 Diluted 47,433 47,242 47,420 47,237 |
Change in Accumulated Other Comprehensive Income (Loss) | The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended June 27, 2021 and June 28, 2020: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income Balance as of December 31, 2020 $ (482) $ (150,257) $ (146,559) $ (297,298) Other comprehensive (loss) income before reclassifications (574) 9 (17,995) (18,560) Amounts reclassified from accumulated other comprehensive income 998 2,900 — 3,898 Net current-period other comprehensive income (loss) 424 2,909 (17,995) (14,662) Balance as of June 27, 2021 $ (58) $ (147,348) $ (164,554) $ (311,960) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income Balance as of December 31, 2019 $ 735 $ (138,810) $ (206,317) $ (344,392) Other comprehensive (loss) income before reclassifications (4,189) 183 (545) (4,551) Amounts reclassified from accumulated other comprehensive loss (723) 2,851 — 2,128 Net current-period other comprehensive (loss) income (4,912) 3,034 (545) (2,423) Balance as of June 28, 2020 $ (4,177) $ (135,776) $ (206,862) $ (346,815) |
Reclassification of Gain/Losses into Income/Expense, Net of Tax | The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended June 27, 2021 and June 28, 2020: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Losses (gains) on foreign exchange contracts: Cost of goods sold $ 133 $ (685) $ 979 $ (751) Total before tax 133 (685) 979 (751) Taxes 27 19 19 28 Net of tax $ 160 $ (666) $ 998 $ (723) Amortization of pension and other postretirement benefit items (1) : Actuarial losses $ 2,144 $ 1,850 $ 4,287 $ 3,702 Prior-service costs (251) 8 (502) 16 Total before tax 1,893 1,858 3,785 3,718 Tax benefit (443) (433) (885) (867) Net of tax $ 1,450 $ 1,425 $ 2,900 $ 2,851 Total reclassifications, net of tax $ 1,610 $ 759 $ 3,898 $ 2,128 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans. |
Taxes on income from continui_2
Taxes on income from continuing operations (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Income Tax Disclosure [Abstract] | |
Effective Income Tax Rate | Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Effective income tax rate 16.5% 50.9% 15.4% 13.8% |
Segment information (Tables)
Segment information (Tables) | 6 Months Ended |
Jun. 27, 2021 | |
Segment Reporting [Abstract] | |
Segment Results | The following tables present our segment results for the three and six months ended June 27, 2021 and June 28, 2020: Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Americas $ 414,785 $ 312,490 $ 790,278 $ 670,492 EMEA 157,129 131,643 298,382 287,767 Asia 80,603 67,069 144,293 120,198 OEM 60,956 55,832 114,445 119,219 Net revenues $ 713,473 $ 567,034 $ 1,347,398 $ 1,197,676 Three Months Ended Six Months Ended June 27, 2021 June 28, 2020 June 27, 2021 June 28, 2020 Americas $ 105,379 $ 47,539 $ 188,981 $ 188,507 EMEA 23,301 14,923 46,296 35,342 Asia 23,188 13,626 38,104 23,858 OEM 15,262 12,244 27,824 27,343 Total segment operating profit (1) 167,130 88,332 301,205 275,050 Unallocated expenses (2) (38,510) (49,522) (69,151) (79,154) Income from continuing operations before interest and taxes $ 128,620 $ 38,810 $ 232,054 $ 195,896 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges and gain on sale of assets. |
Net revenues (Details)
Net revenues (Details) - Sales Revenue, Net - Customer Concentration Risk | 6 Months Ended |
Jun. 27, 2021 | |
Hospitals And Healthcare Providers | |
Concentration Risk [Line Items] | |
Percentage of total revenue | 89.00% |
Other Medical Device Manufacturers | |
Concentration Risk [Line Items] | |
Percentage of total revenue | 9.00% |
Home Care Providers | |
Concentration Risk [Line Items] | |
Percentage of total revenue | 2.00% |
Net revenues Other revenues (De
Net revenues Other revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Revenue, Major Customer [Line Items] | ||||
Net revenues | $ 713,473 | $ 567,034 | $ 1,347,398 | $ 1,197,676 |
Vascular access | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | 167,739 | 164,958 | 331,712 | 315,214 |
Anesthesia | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | 95,426 | 64,867 | 180,283 | 140,569 |
Interventional | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | 112,082 | 82,594 | 208,255 | 182,525 |
Surgical | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | 98,185 | 67,275 | 178,571 | 142,707 |
Interventional urology | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | 92,243 | 40,094 | 165,607 | 114,286 |
OEM | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | 60,956 | 55,832 | 114,445 | 119,219 |
Other | ||||
Revenue, Major Customer [Line Items] | ||||
Net revenues | $ 86,842 | $ 91,414 | $ 168,525 | $ 183,156 |
Acquisitions and Divestitures -
Acquisitions and Divestitures - Additional Information (Details) - USD ($) $ in Millions | Jun. 28, 2021 | Dec. 28, 2020 | Jun. 27, 2021 | Jun. 27, 2021 | Dec. 31, 2020 | Dec. 31, 2023 | May 15, 2021 |
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations | |||||||
Business Acquisition [Line Items] | |||||||
Disposal group, including discontinued operation, consideration | $ 286 | ||||||
Disposal group, including discontinued operation, working capital | $ 12 | ||||||
Revenue attributable to respiratory business | $ 29.6 | $ 60.7 | $ 138.5 | ||||
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations | Forecast | |||||||
Business Acquisition [Line Items] | |||||||
Proceeds from divestiture of businesses | $ 15 | ||||||
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations | Subsequent event | |||||||
Business Acquisition [Line Items] | |||||||
Proceeds from divestiture of businesses | $ 259 | ||||||
Gain on disposition of business | $ 100 | ||||||
Z-Medica, LLC | |||||||
Business Acquisition [Line Items] | |||||||
Business combination, consideration transferred | $ 500 | ||||||
Maximum additional payment upon completion of certain milestones | $ 25 |
Acquisitions and Divestitures_2
Acquisitions and Divestitures - Assets held-for-sale (Details) - USD ($) $ in Thousands | Jun. 27, 2021 | Dec. 31, 2020 |
Assets | ||
Current assets held-for-sale | $ 26,936 | $ 0 |
Noncurrent assets held-for-sale | 95,426 | $ 0 |
Respiratory Business | Disposal Group, Held-for-sale, Not Discontinued Operations | ||
Assets | ||
Inventories | 26,936 | |
Current assets held-for-sale | 26,936 | |
Property, plant and equipment, net | 17,006 | |
Intangible assets, net | 41,583 | |
Goodwill | 35,745 | |
Operating lease assets | 1,053 | |
Other assets | 39 | |
Noncurrent assets held-for-sale | 95,426 | |
Total assets held-for-sale | 122,362 | |
Liabilities | ||
Other current liabilities | 488 | |
Noncurrent operating lease liabilities | 568 | |
Liabilities held-for-sale | $ 1,056 |
Restructuring and impairment _3
Restructuring and impairment charges - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |
Jun. 27, 2021 | Jun. 27, 2021 | Jun. 28, 2020 | |
Restructuring Cost and Reserve [Line Items] | |||
Asset impairment charges | $ 6,739 | $ 6,739 | $ 0 |
Termination benefits | Respiratory divestiture plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring reserve | 2,500 | 2,500 | |
Termination benefits | 2021 Restructuring plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Restructuring reserve | 5,100 | 5,100 | |
Other Restructuring costs | |||
Restructuring Cost and Reserve [Line Items] | |||
Asset impairment charges | 6,739 | 6,739 | |
Minimum | Respiratory divestiture plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Aggregate capital expenditures | 22,000 | ||
Expected restructuring charges | 24,000 | 24,000 | |
Minimum | Termination benefits | 2021 Restructuring plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Expected restructuring charges | 7,000 | 7,000 | |
Minimum | Other Restructuring costs | 2021 Restructuring plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Expected restructuring charges | 3,000 | 3,000 | |
Maximum | Respiratory divestiture plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Aggregate capital expenditures | 28,000 | ||
Expected restructuring charges | 30,000 | 30,000 | |
Maximum | Termination benefits | 2021 Restructuring plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Expected restructuring charges | 9,000 | 9,000 | |
Maximum | Other Restructuring costs | 2021 Restructuring plan | |||
Restructuring Cost and Reserve [Line Items] | |||
Expected restructuring charges | $ 4,000 | $ 4,000 |
Restructuring and impairment _4
Restructuring and impairment charges - Expected Costs to be Incurred (Details) $ in Millions | 3 Months Ended | 6 Months Ended |
Jun. 27, 2021USD ($) | Jun. 27, 2021USD ($) | |
2019 Footprint realignment plan | ||
Restructuring Cost and Reserve [Line Items] | ||
Aggregate restructuring charges | $ 15.5 | |
Restructuring reserve | $ 5.4 | 5.4 |
Restructuring expenses | 3.9 | 7.4 |
Aggregate restructuring related charges | 28.6 | |
2019 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 54 | 54 |
Expected cash outlays | 48 | 48 |
Expected capital expenditures | 28 | 28 |
2019 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 61 | 61 |
Expected cash outlays | 55 | 55 |
Expected capital expenditures | 33 | 33 |
2018 Footprint realignment plan | ||
Restructuring Cost and Reserve [Line Items] | ||
Aggregate restructuring charges | 61.9 | |
Restructuring reserve | 47.2 | 47.2 |
Restructuring expenses | 2.3 | 4.3 |
Aggregate restructuring related charges | 21 | |
2018 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 103 | 103 |
Expected cash outlays | 99 | 99 |
Expected capital expenditures | 19 | 19 |
2018 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 133 | 133 |
Expected cash outlays | 127 | 127 |
Expected capital expenditures | 23 | 23 |
2014 Footprint realignment plan | ||
Restructuring Cost and Reserve [Line Items] | ||
Aggregate restructuring charges | 13.7 | |
Restructuring reserve | 3.1 | 3.1 |
Restructuring expenses | 1 | 1.7 |
Aggregate restructuring related charges | 37.7 | |
2014 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 52 | 52 |
Expected cash outlays | 42 | 42 |
Expected capital expenditures | 26 | 26 |
2014 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 55 | 55 |
Expected cash outlays | 46 | 46 |
Expected capital expenditures | 27 | 27 |
Respiratory divestiture plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 24 | 24 |
Respiratory divestiture plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 30 | 30 |
Termination benefits | 2019 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 14 | 14 |
Termination benefits | 2019 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 16 | 16 |
Termination benefits | 2018 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 60 | 60 |
Termination benefits | 2018 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 70 | 70 |
Termination benefits | 2014 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 13 | 13 |
Termination benefits | 2014 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 13 | 13 |
Termination benefits | Respiratory divestiture plan | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring reserve | 2.5 | 2.5 |
Other Restructuring costs | 2019 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 2 | 2 |
Other Restructuring costs | 2019 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 2 | 2 |
Other Restructuring costs | 2018 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 3 | 3 |
Other Restructuring costs | 2018 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 4 | 4 |
Other Restructuring costs | 2014 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 1 | 1 |
Other Restructuring costs | 2014 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 2 | 2 |
Special Termination Benefit And Other Restructuring | 2019 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 16 | 16 |
Special Termination Benefit And Other Restructuring | 2019 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 18 | 18 |
Special Termination Benefit And Other Restructuring | 2018 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 63 | 63 |
Special Termination Benefit And Other Restructuring | 2018 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 74 | 74 |
Special Termination Benefit And Other Restructuring | 2014 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 14 | 14 |
Special Termination Benefit And Other Restructuring | 2014 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 15 | 15 |
Special Termination Benefit And Other Restructuring | Respiratory divestiture plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 5 | 5 |
Special Termination Benefit And Other Restructuring | Respiratory divestiture plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 8 | 8 |
Accelerated Depreciation And Other Costs | 2019 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 38 | 38 |
Accelerated Depreciation And Other Costs | 2019 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 43 | 43 |
Accelerated Depreciation And Other Costs | 2018 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 40 | 40 |
Accelerated Depreciation And Other Costs | 2018 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 59 | 59 |
Accelerated Depreciation And Other Costs | 2014 Footprint realignment plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 38 | 38 |
Accelerated Depreciation And Other Costs | 2014 Footprint realignment plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 40 | 40 |
Accelerated Depreciation And Other Costs | Respiratory divestiture plan | Minimum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | 19 | 19 |
Accelerated Depreciation And Other Costs | Respiratory divestiture plan | Maximum | ||
Restructuring Cost and Reserve [Line Items] | ||
Expected restructuring charges | $ 22 | $ 22 |
Restructuring and impairment _5
Restructuring and impairment charges - Charges Recognized (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | $ 4,755 | $ 19,005 | $ 12,753 | $ 20,351 |
Asset impairment charges | 6,739 | 6,739 | 0 | |
Restructuring and impairment charges | 11,494 | 19,005 | 19,492 | 20,351 |
Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 3,823 | 18,601 | 11,025 | 19,637 |
Asset impairment charges | 0 | 0 | ||
Restructuring and impairment charges | 3,823 | 11,025 | ||
Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 932 | 404 | 1,728 | 714 |
Asset impairment charges | 6,739 | 6,739 | ||
Restructuring and impairment charges | 7,671 | 8,467 | ||
Respiratory divestiture plan | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 2,541 | 2,541 | ||
Respiratory divestiture plan | Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 2,540 | 2,540 | ||
Respiratory divestiture plan | Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 1 | 1 | ||
2021 Restructuring plan | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 152 | 6,912 | ||
2021 Restructuring plan | Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 129 | 6,889 | ||
2021 Restructuring plan | Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 23 | 23 | ||
2020 Workforce reduction plan | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 10,564 | 10,564 | ||
2020 Workforce reduction plan | Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 10,564 | 10,564 | ||
2020 Workforce reduction plan | Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 0 | 0 | ||
2019 Footprint realignment plan | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | (210) | 405 | 236 | 1,243 |
2019 Footprint realignment plan | Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | (301) | 323 | 40 | 1,152 |
2019 Footprint realignment plan | Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 91 | 82 | 196 | 91 |
2018 Footprint realignment plan | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 1,551 | 7,597 | 1,863 | 7,992 |
2018 Footprint realignment plan | Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 1,459 | 7,545 | 1,726 | 7,859 |
2018 Footprint realignment plan | Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 92 | 52 | 137 | 133 |
Other restructuring programs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | 721 | 439 | 1,201 | 552 |
Other restructuring programs | Termination benefits | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | (4) | 169 | (170) | 62 |
Other restructuring programs | Other Restructuring costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | $ 725 | $ 270 | $ 1,371 | $ 490 |
Inventories (Detail)
Inventories (Detail) - USD ($) $ in Thousands | Jun. 27, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 133,722 | $ 132,370 |
Work-in-process | 78,088 | 75,874 |
Finished goods | 278,508 | 304,952 |
Inventories | $ 490,318 | $ 513,196 |
Goodwill and other intangible_3
Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands | 6 Months Ended |
Jun. 27, 2021USD ($) | |
Goodwill [Roll Forward] | |
Goodwill, beginning balance | $ 2,585,966 |
Goodwill held-for-sale | (35,745) |
Currency translation adjustment | (12,789) |
Goodwill, ending balance | 2,537,432 |
Americas | |
Goodwill [Roll Forward] | |
Goodwill, beginning balance | 1,700,282 |
Goodwill held-for-sale | (21,802) |
Currency translation adjustment | 1,081 |
Goodwill, ending balance | 1,679,561 |
EMEA | |
Goodwill [Roll Forward] | |
Goodwill, beginning balance | 536,228 |
Goodwill held-for-sale | (7,537) |
Currency translation adjustment | (9,507) |
Goodwill, ending balance | 519,184 |
Asia | |
Goodwill [Roll Forward] | |
Goodwill, beginning balance | 237,446 |
Goodwill held-for-sale | (6,406) |
Currency translation adjustment | (4,363) |
Goodwill, ending balance | 226,677 |
OEM | |
Goodwill [Roll Forward] | |
Goodwill, beginning balance | 112,010 |
Goodwill held-for-sale | 0 |
Currency translation adjustment | 0 |
Goodwill, ending balance | $ 112,010 |
Goodwill and other intangible_4
Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands | Jun. 27, 2021 | Dec. 31, 2020 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 3,411,842 | $ 3,534,799 |
Accumulated Amortization | (1,030,513) | (1,015,053) |
In-process research and development | ||
Finite-Lived Intangible Assets [Line Items] | ||
Indefinite-lived intangible assets | 29,136 | 29,627 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets | 1,335,685 | 1,377,943 |
Accumulated Amortization | (414,086) | (425,692) |
Intellectual property | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets | 1,444,105 | 1,458,924 |
Accumulated Amortization | (519,239) | (479,612) |
Distribution rights | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets | 23,722 | 23,866 |
Accumulated Amortization | (20,525) | (20,280) |
Trade names | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets | 555,192 | 619,847 |
Accumulated Amortization | (53,519) | (65,955) |
Non-compete agreements | ||
Finite-Lived Intangible Assets [Line Items] | ||
Finite-lived intangible assets | 24,002 | 24,592 |
Accumulated Amortization | $ (23,144) | $ (23,514) |
Borrowings - Components of long
Borrowings - Components of long-term debt (Details) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 27, 2021 | Apr. 29, 2021 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | |||
Long-term debt, gross | $ 2,323,000 | $ 2,498,000 | |
Less: Unamortized debt issuance costs | (14,834) | (19,612) | |
Total long-term debt | 2,308,166 | 2,478,388 | |
Current borrowings | (92,500) | (100,500) | |
Long-term borrowings | 2,215,666 | 2,377,888 | |
Revolving Credit Facility | |||
Debt Instrument [Line Items] | |||
Long-term line of credit | $ 600,500 | 350,000 | |
Line of credit facility interest rate | 1.59% | ||
Term Loan | |||
Debt Instrument [Line Items] | |||
Long-term line of credit | $ 647,500 | 673,000 | |
Line of credit facility interest rate | 1.59% | ||
Senior Notes | 4.875% Senior Notes due 2026 | |||
Debt Instrument [Line Items] | |||
Senior notes | $ 0 | $ 400,000 | 400,000 |
Debt instrument, stated interest rate | 4.875% | 4.875% | |
Senior Notes | 4.625% Senior Notes due 2027 | |||
Debt Instrument [Line Items] | |||
Senior notes | $ 500,000 | 500,000 | |
Debt instrument, stated interest rate | 4.625% | ||
Senior Notes | 4.25% Senior Notes due 2028 | |||
Debt Instrument [Line Items] | |||
Senior notes | $ 500,000 | 500,000 | |
Debt instrument, stated interest rate | 4.25% | ||
Securitization program | |||
Debt Instrument [Line Items] | |||
Securitization program | $ 75,000 | $ 75,000 | |
Debt instrument, stated interest rate | 1.20% |
Borrowings - Additional Informa
Borrowings - Additional Information (Details) - USD ($) $ in Thousands | Jul. 06, 2021 | Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | Apr. 29, 2021 | Dec. 31, 2020 |
Line of Credit Facility [Line Items] | |||||||
Loss on extinguishment of debt | $ 12,986 | $ 0 | $ 12,986 | $ 0 | |||
Senior Notes | 4.875% Senior Notes due 2026 | |||||||
Line of Credit Facility [Line Items] | |||||||
Senior notes | $ 0 | $ 0 | $ 400,000 | $ 400,000 | |||
Debt instrument, stated interest rate | 4.875% | 4.875% | 4.875% | ||||
Debt instrument, redemption price, percentage | 102.438% | ||||||
Loss on extinguishment of debt | $ 13,000 | ||||||
Revolving Credit Facility | Subsequent event | |||||||
Line of Credit Facility [Line Items] | |||||||
Repayment of lines of credit | $ 259,000 |
Financial instruments - Additio
Financial instruments - Additional Information (Details) € in Millions | 3 Months Ended | 6 Months Ended | |||||||
Jun. 27, 2021USD ($) | Jun. 28, 2020USD ($) | Jun. 27, 2021USD ($) | Jun. 28, 2020USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($)Financial_Institution_Counterparty | Dec. 31, 2019EUR (€)Financial_Institution_Counterparty | Dec. 31, 2018USD ($)Financial_Institution_Counterparty | Dec. 31, 2018EUR (€)Financial_Institution_Counterparty | |
Derivatives Fair Value [Line Items] | |||||||||
Allowance for credit losses | $ 12,100,000 | $ 12,100,000 | $ 12,900,000 | ||||||
Allowance for credit losses, current | 7,100,000 | 7,100,000 | 8,100,000 | ||||||
Cash flow hedging | |||||||||
Derivatives Fair Value [Line Items] | |||||||||
Ineffectiveness related to derivatives | 0 | $ 0 | 0 | $ 0 | |||||
Foreign exchange contract | Not Designated as Hedging Instrument | |||||||||
Derivatives Fair Value [Line Items] | |||||||||
Gain related to currency forward contracts | 700,000 | $ 800,000 | |||||||
Loss related to currency forward contracts | $ 800,000 | 2,500,000 | |||||||
Total notional amount for all open foreign currency forward contracts | 189,200,000 | $ 189,200,000 | 163,500,000 | ||||||
Derivative, term of contract | 12 months | ||||||||
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | |||||||||
Derivatives Fair Value [Line Items] | |||||||||
Total notional amount for all open foreign currency forward contracts | $ 137,000,000 | $ 137,000,000 | $ 129,500,000 | ||||||
Cross-currency interest rate swaps | Designated as Hedging Instrument | |||||||||
Derivatives Fair Value [Line Items] | |||||||||
Total notional amount for all open foreign currency forward contracts | $ 250,000,000 | € 219.2 | $ 500,000,000 | € 433.9 | |||||
Derivative, number of instruments held | Financial_Institution_Counterparty | 5 | 5 | 6 | 6 | |||||
Derivative, fixed interest rate | 4.875% | 4.875% | 4.625% | 4.625% | |||||
Derivative, annual interest rate | 2.4595% | 2.4595% | 1.942% | 1.942% |
Financial instruments - Foreign
Financial instruments - Foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Foreign exchange (losses) gains | $ 6,080 | $ 17,654 | $ (17,995) | $ (545) |
Interest benefit | 9,126 | 9,805 | ||
Cross-currency interest rate swaps | Cash flow hedging | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Foreign exchange (losses) gains | (7,127) | (7,408) | 10,487 | 17,607 |
Cross-currency interest rate swaps | Not Designated as Hedging Instrument | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Interest benefit | $ 4,479 | $ 4,931 | $ 9,126 | $ 9,805 |
Financial instruments - Fair va
Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands | Jun. 27, 2021 | Dec. 31, 2020 |
Cash flow hedging | ||
Derivatives Fair Value [Line Items] | ||
Total asset derivatives | $ 21,905 | $ 21,858 |
Total liability derivatives | 22,985 | 35,995 |
Foreign exchange contract | Other liabilities | ||
Derivatives Fair Value [Line Items] | ||
Total liability derivatives | 21,183 | 34,125 |
Foreign exchange contract | Cash flow hedging | Prepaid expenses and other current assets | ||
Derivatives Fair Value [Line Items] | ||
Total asset derivatives | 21,905 | 21,858 |
Foreign exchange contract | Cash flow hedging | Other current liabilities | ||
Derivatives Fair Value [Line Items] | ||
Total liability derivatives | 1,802 | 1,870 |
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets | ||
Derivatives Fair Value [Line Items] | ||
Total asset derivatives | 1,199 | 1,691 |
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities | ||
Derivatives Fair Value [Line Items] | ||
Total liability derivatives | 1,372 | 1,504 |
Foreign exchange contract | Not Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets | ||
Derivatives Fair Value [Line Items] | ||
Total asset derivatives | 73 | 61 |
Foreign exchange contract | Not Designated as Hedging Instrument | Cash flow hedging | Other current liabilities | ||
Derivatives Fair Value [Line Items] | ||
Total liability derivatives | 430 | 366 |
Cross-currency interest rate swaps | Not Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets | ||
Derivatives Fair Value [Line Items] | ||
Total asset derivatives | 20,633 | 20,106 |
Cross-currency interest rate swaps | Not Designated as Hedging Instrument | Cash flow hedging | Other liabilities | ||
Derivatives Fair Value [Line Items] | ||
Total liability derivatives | $ 21,183 | $ 34,125 |
Fair value measurement - Financ
Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands | Jun. 27, 2021 | Dec. 31, 2020 |
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] | ||
Investments in marketable securities | $ 14,287 | $ 12,617 |
Derivative assets | 21,905 | 21,858 |
Derivative liabilities | 22,985 | 35,995 |
Contingent consideration liabilities | 13,974 | 36,633 |
Quoted prices in active markets (Level 1) | ||
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] | ||
Investments in marketable securities | 14,287 | 12,617 |
Derivative assets | 0 | 0 |
Derivative liabilities | 0 | 0 |
Contingent consideration liabilities | 0 | 0 |
Significant other observable Inputs (Level 2) | ||
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] | ||
Investments in marketable securities | 0 | 0 |
Derivative assets | 21,905 | 21,858 |
Derivative liabilities | 22,985 | 35,995 |
Contingent consideration liabilities | 0 | 0 |
Significant unobservable Inputs (Level 3) | ||
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items] | ||
Investments in marketable securities | 0 | 0 |
Derivative assets | 0 | 0 |
Derivative liabilities | 0 | 0 |
Contingent consideration liabilities | $ 13,974 | $ 36,633 |
Fair value measurement - Valuat
Fair value measurement - Valuation technique and inputs used in determining the fair value of contingent consideration (Details) - Discounted cash flow - Discount rate | Jun. 27, 2021 |
Milestone-based payments | Minimum | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Business combination, contingent consideration, liability, measurement input | 0.012 |
Milestone-based payments | Maximum | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Business combination, contingent consideration, liability, measurement input | 0.025 |
Milestone-based payments | Weighted Average | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Business combination, contingent consideration, liability, measurement input | 0.019 |
Revenue-based payments | Minimum | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Business combination, contingent consideration, liability, measurement input | 0.013 |
Revenue-based payments | Maximum | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Business combination, contingent consideration, liability, measurement input | 0.100 |
Revenue-based payments | Weighted Average | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Business combination, contingent consideration, liability, measurement input | 0.044 |
Fair value measurement - Reconc
Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended |
Jun. 27, 2021 | Jun. 27, 2021 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Beginning balance | $ 36,633 | |
Payments | (30,489) | |
Revaluations | 7,848 | |
Translation adjustments | (18) | |
Ending balance | $ 13,974 | 13,974 |
Essential Medical, Inc. | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Settlement payment | $ 17,400 | $ 17,400 |
Shareholders' equity - Addition
Shareholders' equity - Additional Information (Details) - shares shares in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Equity [Abstract] | ||||
Weighted average antidilutive shares which were not included in the calculation of earnings per share | 0.1 | 0.2 | 0.1 | 0.1 |
Shareholders' equity - Reconcil
Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Equity [Abstract] | ||||
Basic (in shares) | 46,741 | 46,442 | 46,719 | 46,412 |
Dilutive effect of share-based awards (in shares) | 692 | 800 | 701 | 825 |
Diluted (in shares) | 47,433 | 47,242 | 47,420 | 47,237 |
Shareholders' equity - Change i
Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 27, 2021 | Jun. 28, 2020 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Beginning Balance | $ 3,336,457 | $ 2,979,320 |
Other comprehensive (loss) income before reclassifications | (18,560) | (4,551) |
Amounts reclassified from accumulated other comprehensive income | 3,898 | 2,128 |
Net current-period other comprehensive income (loss) | (14,662) | (2,423) |
Ending Balance | 3,466,102 | 3,097,402 |
Cash Flow Hedges | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Beginning Balance | (482) | 735 |
Other comprehensive (loss) income before reclassifications | (574) | (4,189) |
Amounts reclassified from accumulated other comprehensive income | 998 | (723) |
Net current-period other comprehensive income (loss) | 424 | (4,912) |
Ending Balance | (58) | (4,177) |
Pension and Other Postretirement Benefit Plans | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Beginning Balance | (150,257) | (138,810) |
Other comprehensive (loss) income before reclassifications | 9 | 183 |
Amounts reclassified from accumulated other comprehensive income | 2,900 | 2,851 |
Net current-period other comprehensive income (loss) | 2,909 | 3,034 |
Ending Balance | (147,348) | (135,776) |
Foreign Currency Translation Adjustment | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Beginning Balance | (146,559) | (206,317) |
Other comprehensive (loss) income before reclassifications | (17,995) | (545) |
Amounts reclassified from accumulated other comprehensive income | 0 | 0 |
Net current-period other comprehensive income (loss) | (17,995) | (545) |
Ending Balance | (164,554) | (206,862) |
Accumulated Other Comprehensive (Loss) Income | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Beginning Balance | (297,298) | (344,392) |
Ending Balance | $ (311,960) | $ (346,815) |
Shareholders' equity - Accumula
Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Cost of goods sold | $ 315,917 | $ 288,662 | $ 605,315 | $ 585,680 |
Total before tax | 99,695 | 23,291 | 186,990 | 165,517 |
(Benefit) tax | (16,412) | (11,848) | (28,840) | (22,922) |
Net of tax | 83,283 | 11,443 | 158,150 | 142,595 |
Reclassification out of Accumulated Other Comprehensive Income | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total reclassifications, net of tax | 1,610 | 759 | 3,898 | 2,128 |
Reclassification out of Accumulated Other Comprehensive Income | Pension and Other Postretirement Benefits Plans | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total before tax | 1,893 | 1,858 | 3,785 | 3,718 |
(Benefit) tax | (443) | (433) | (885) | (867) |
Net of tax | 1,450 | 1,425 | 2,900 | 2,851 |
Reclassification out of Accumulated Other Comprehensive Income | Actuarial losses | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total before tax | 2,144 | 1,850 | 4,287 | 3,702 |
Reclassification out of Accumulated Other Comprehensive Income | Prior-service costs | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Total before tax | (251) | 8 | (502) | 16 |
Reclassification out of Accumulated Other Comprehensive Income | Foreign exchange contract | Cash Flow Hedges | ||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
Cost of goods sold | 133 | (685) | 979 | (751) |
Total before tax | 133 | (685) | 979 | (751) |
(Benefit) tax | 27 | 19 | 19 | 28 |
Net of tax | $ 160 | $ (666) | $ 998 | $ (723) |
Taxes on income from continui_3
Taxes on income from continuing operations (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Income Tax Disclosure [Abstract] | ||||
Effective income tax rate | 16.50% | 50.90% | 15.40% | 13.80% |
Commitments and contingent li_2
Commitments and contingent liabilities (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |
Jun. 27, 2021 | Mar. 28, 2021 | Jun. 27, 2021 | |
Loss Contingencies [Line Items] | |||
Estimated litigation liability | $ 0.4 | $ 0.4 | |
Essential Medical, Inc. | |||
Loss Contingencies [Line Items] | |||
Settlement payment | 17.4 | $ 17.4 | |
Pending Litigation | |||
Loss Contingencies [Line Items] | |||
Money damages sought | $ 66.9 | ||
Minimum | |||
Loss Contingencies [Line Items] | |||
Estimated time frame over which accrued amounts may be paid out | 10 years | ||
Maximum | |||
Loss Contingencies [Line Items] | |||
Estimated time frame over which accrued amounts may be paid out | 15 years | ||
Accrued Liabilities | |||
Loss Contingencies [Line Items] | |||
Accrual for environmental loss contingencies | 1.6 | $ 1.6 | |
Other Liability | |||
Loss Contingencies [Line Items] | |||
Accrual for environmental loss contingencies | $ 4.9 | $ 4.9 |
Segment information (Details)
Segment information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 27, 2021 | Jun. 28, 2020 | Jun. 27, 2021 | Jun. 28, 2020 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Net revenues | $ 713,473 | $ 567,034 | $ 1,347,398 | $ 1,197,676 |
Operating profit | 128,620 | 38,810 | 232,054 | 195,896 |
Operating Segments | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Operating profit | 167,130 | 88,332 | 301,205 | 275,050 |
Unallocated expenses | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Operating profit | (38,510) | (49,522) | (69,151) | (79,154) |
Americas | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Net revenues | 414,785 | 312,490 | 790,278 | 670,492 |
Americas | Operating Segments | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Operating profit | 105,379 | 47,539 | 188,981 | 188,507 |
EMEA | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Net revenues | 157,129 | 131,643 | 298,382 | 287,767 |
EMEA | Operating Segments | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Operating profit | 23,301 | 14,923 | 46,296 | 35,342 |
Asia | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Net revenues | 80,603 | 67,069 | 144,293 | 120,198 |
Asia | Operating Segments | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Operating profit | 23,188 | 13,626 | 38,104 | 23,858 |
OEM | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Net revenues | 60,956 | 55,832 | 114,445 | 119,219 |
OEM | Operating Segments | ||||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||||
Operating profit | $ 15,262 | $ 12,244 | $ 27,824 | $ 27,343 |